

112TH CONGRESS  
1ST SESSION

# H. R. 1254

To amend the Controlled Substances Act to place synthetic drugs in Schedule I.

---

## IN THE HOUSE OF REPRESENTATIVES

MARCH 30, 2011

Mr. DENT (for himself, Mr. MEEHAN, Mr. MARINO, Mr. PLATTS, Mr. BARLETTA, Mr. CUELLAR, Mrs. EMERSON, Mrs. BIGGERT, Mr. LATOURETTE, Mr. GIBSON, Mr. STIVERS, and Mr. REED) introduced the following bill; which was referred to the Committee on Energy and Commerce, and in addition to the Committee on the Judiciary, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned

---

## A BILL

To amend the Controlled Substances Act to place synthetic drugs in Schedule I.

1 *Be it enacted by the Senate and House of Representa-*  
2 *tives of the United States of America in Congress assembled,*

3 **SECTION 1. SHORT TITLE.**

4 This Act may be cited as the “Synthetic Drug Con-  
5 trol Act of 2011”.

1 **SEC. 2. ADDITION OF SYNTHETIC DRUGS TO SCHEDULE I**  
2 **OF THE CONTROLLED SUBSTANCES ACT.**

3 (a) CANNABIMIMETIC AGENTS.—Schedule I, as set  
4 forth in section 202(c) of the Controlled Substances Act  
5 (21 U.S.C. 812(c)) is amended by adding at the end the  
6 following:

7 “(d)(1) Unless specifically exempted or unless listed  
8 in another schedule, any material, compound, mixture, or  
9 preparation which contains any quantity of  
10 cannabimimetic agents, or which contains their salts, iso-  
11 mers, and salts of isomers whenever the existence of such  
12 salts, isomers, and salts of isomers is possible within the  
13 specific chemical designation.

14 “(2) In paragraph (1), the term ‘cannabimimetic  
15 agents’—

16 “(A) means any substance that is a cannabinoid  
17 receptor type 1 (CB1 receptor) agonist as dem-  
18 onstrated by binding studies and functional assays  
19 within the following structural classes:

20 “(i) 2-(3-hydroxycyclohexyl)phenol with  
21 substitution at the 5-position of the phenolic  
22 ring by alkyl or alkenyl, whether or not sub-  
23 stituted on the cyclohexyl ring to any extent.

24 “(ii) 3-(1-naphthoyl)indole or 3-(1-  
25 naphthyl)indole by substitution at the nitrogen  
26 atom of the indole ring, whether or not further

1 substituted on the indole ring to any extent,  
2 whether or not substituted on the naphthoyl or  
3 naphthyl ring to any extent.

4 “(iii) 3-(1-naphthoyl)pyrrole by substi-  
5 tution at the nitrogen atom of the pyrrole ring,  
6 whether or not further substituted in the indole  
7 ring to any extent, whether or not substituted  
8 on the naphthoyl ring to any extent.

9 “(iv) 1-(1-naphthylmethyl)indene by substi-  
10 tution of the 3-position of the indene ring,  
11 whether or not further substituted in the indene  
12 ring to any extent, whether or not substituted  
13 on the naphthyl ring to any extent.

14 “(v) 3-phenylacetylindole or 3-  
15 benzoylindole by substitution at the nitrogen  
16 atom of the indole ring, whether or not further  
17 substituted in the indole ring to any extent,  
18 whether or not substituted on the phenyl ring  
19 to any extent.; and

20 “(B) includes—

21 “(i) 5-(1,1-dimethylheptyl)-2-[(1R,3S)-3-  
22 hydroxycyclohexyl]-phenol (CP-47,497);

23 “(ii) 5-(1,1-dimethyloctyl)-2-[(1R,3S)-3-  
24 hydroxycyclohexyl]-phenol (cannabicyclohexanol  
25 or CP-47,497 C8-homolog);

- 1                   “(iii)           1-pentyl-3-(1-naphthoyl)indole  
2                   (JWH-018 and AM678);
- 3                   “(iv) 1-butyl-3-(1-naphthoyl)indole (JWH-  
4                   073);
- 5                   “(v) 1-hexyl-3-(1-naphthoyl)indole (JWH-  
6                   019);
- 7                   “(vi) 1-[2-(4-morpholinyl)ethyl]-3-(1-naph-  
8                   thoyl)indole (JWH-200);
- 9                   “(vii)                           1-pentyl-3-(2-  
10                   methoxyphenylacetyl)indole (JWH-250);
- 11                   “(viii)                           1-pentyl-3-[1-(4-  
12                   methoxynaphthoyl)]indole (JWH-081);
- 13                   “(ix)           1-pentyl-3-(4-methyl-1-naph-  
14                   thoyl)indole (JWH-122);
- 15                   “(x)           1-pentyl-3-(4-chloro-1-naph-  
16                   thoyl)indole (JWH-398);
- 17                   “(xi)           1-(5-fluoropentyl)-3-(1-naph-  
18                   thoyl)indole (AM2201);
- 19                   “(xii)                           1-(5-fluoropentyl)-3-(2-  
20                   iodobenzoyl)indole (AM694);
- 21                   “(xiii)           1-pentyl-3-[(4-methoxy)-ben-  
22                   zoyl]indole (SR-19 and RCS-4);
- 23                   “(xiv)                           1-cyclohexylethyl-3-(2-  
24                   methoxyphenylacetyl)indole (SR-18 and RCS-  
25                   8); and



1           “(30)                           3,4-methylenedioxy-alpha-  
2           pyrrolidinopropiophenone (MDPPP).

3           “(31) Alpha-pyrrolidinovalerophenone (alpha-  
4           PVP).

5           “(32) 6,7-dihydro-5H-indeno(5,6-d)-1,3-dioxal-  
6           6-amine) (MDAI).”.

7   **SEC. 3. TEMPORARY SCHEDULING TO AVOID IMMINENT**  
8                           **HAZARDS TO PUBLIC SAFETY EXPANSION.**

9           Section 201(h)(2) of the Controlled Substances Act  
10 (21 U.S.C. 811(h)(2)) is amended—

11           (1) by striking “one year” and inserting “2  
12           years”; and

13           (2) by striking “six months” and inserting “1  
14           year”.

○